Simultaneous multi-orientation (“SMO”) magnetic resonance imaging (“MRI”), in which arbitrarily-oriented slices are simultaneously imaged, is described. The SMO techniques can include any number of pulse sequences that are adapted to acquire data from two or more arbitrarily oriented slices. In general, an SMO acquisition includes sequentially exciting two or more arbitrarily rotated slices that share a common spatial encoding axis (e.g., a common frequency encoding direction) and simultaneously acquiring data from the excited slices.
G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
2.
ENDOTRACHEAL TUBE PLACEMENT CONFIRMATION AND DISPLACEMENT MONITORING
Systems and methods for endotracheal tube (ETT) placement confirmation and/or displacement monitoring includes an ETT that includes an optical fiber running substantially along a length of the ETT. The ETT has an insertion end and the optical fiber includes a tip proximate to the insertion end of the ETT. A source of near-infrared (NIR) wavelength light is operably connected to the optical fiber. A detection system is spaced apart from the ETT and the optical fiber. The detection system is configured for noninvasive detection of NIR wavelength light emitted from the optical fiber and diffused through the patient. A processor is communicatively connected to the detection system and configured to receive data from the detection system. The processor is configured to determine an initial position of the tip of the optical fiber and to continuously monitor subsequent position of the tip of the optical fiber.
Methods for preventing or slowing the progression of cognitive impairment or preventing the development or reducing the rate of cognitive decline in a subject displaying or presenting with cognitive performance within the normal range for the subject's age. The methods comprise administering to the subject one or more of levetiracetam, brivaracetam or seletracetam, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and a pharmaceutically acceptable carrier, a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, a pharmaceutical composition comprising a GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph thereof, and a pharmaceutically acceptable carrier, or a combination or a composition comprising the levetiracetam, brivaracetam or seletracetam or pharmaceutical salt thereof and the GABAA α5 receptor agonist or a pharmaceutically acceptable salt, hydrate, solvate, isomer, or polymorph. In some embodiments, the subjects have one or more risk factors that are predictive for or associated with the development or progression of cognitive impairment or decline.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
4.
GENERATION OF NANOPARTICLES WITH ACELLULAR PORCINE BONE FOR ORTHOPEDIC REGENERATION AND IMAGING
A composition is disclosed for orthopedic regeneration. The composition comprises bone extracellular matrix particles, wherein the particles have an average particle size in a range of 1 nanometer to 500 nanometers. The composition can further comprise a fluorescent dye associated with each particle of at least a portion of the particles. The composition can further comprise one or more bioactive agents associated with each particle of at least a portion of the particles. Also disclosed are methods of making the compositions.
Provided herein are methods and compositions for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle or inner ear for rapid, localized treatment and prevention of diseases and conditions associated with a middle ear infection. In particular, provided herein are anionic and polymer-based nanoparticles that provide a platform for delivery of therapeutic cargo, as well as anionic and polymer-based nanoparticle compositions for rapid, localized delivery of therapeutic agents to the middle or inner ear.
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
6.
SYSTEM AND METHOD FOR EXTRACORPOREAL BLOOD FILTRATION
Extracorporeal organ (e.g., liver) perfusion is implemented to filter a patient's blood without direct interaction between the patient blood and the organ used for perfusion. Plasma is separated from the patient's blood and mixed with an isolated perfusate circulating in the machine perfusion system. The plasma-perfusate mixture is circulated through the organ to generate a filtered plasma-perfusate mixture. Filtered plasma is separated from the filtered plasma-perfusate mixture and reintegrated with the cell-rich patient blood, which is then circulated to the patient as filtered blood. In this way, blood components such as platelets are isolated from the organ in the machine perfusion system, while the plasma is filtered by the organ to provide removal of toxins or other waste in the patient blood.
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE MEDICAL COLLEGE OF WISCONSIN, INC. (USA)
Inventor
Ku, Zhiqiang
Zhang, Ningyan
An, Zhiqiang
Geethadevi, Anjali
Pradeep, Sunila
Chaluvally-Raghavan, Pradeep
Abstract
Isolated or recombinant anti-OSMR monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides methods of treating lysosomal storage disorders, e.g., Fabry disease, Gaucher disease, Farber disease, and Pompe disease. The method comprises producing vector-transduced T-Rapa cells that express a transgene of interest and administering the cells to a patient in need thereof. The T-Rapa cells may be transduced with a dual promoter lentivirus vector.
Functional activation-based analysis of deep neural networks uses a structured set of inputs (e.g., input datasets corresponding to different knowledge or datatype domains) are sequentially provided to a pretrained neural network (e.g., according to a block-sequence). The output values for each node in the neural network are recorded and stored as a time-series of layer output values. A statistical analysis of the time-series of layer output values may be fit as a function of the structured set of inputs to generate neural network analysis data that indicate activations of layers within the neural network based on the inputs.
Functional activation-based analysis of deep neural networks uses a structured set of inputs (e.g., input datasets corresponding to different knowledge or datatype domains) are sequentially provided to a pretrained neural network (e.g., according to a block-sequence). The output values for each node in the neural network are recorded and stored as a time-series of layer output values. A statistical analysis of the time-series of layer output values may be fit as a function of the structured set of inputs to generate neural network analysis data that indicate activations of layers within the neural network based on the inputs.
Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.
Systems and methods for estimating quantitative histological features of a subject's tissue based on medical images of the subject are provided. For instance, quantitative histological features of a tissue are estimated by comparing medical images of the subject to a trained model that relates histological features to multiple different medical image contrast types, whether from one medical imaging modality or multiple different medical imaging modalities. In general, the trained model is generated based on medical images of ex vivo samples, in vitro samples, in vivo samples or combinations thereof, and is based on histological features extracted from those samples. A machine learning algorithm, or other suitable learning algorithm, is used to generate the trained model. The trained model is not patient-specific and thus, once generated, can be applied to any number of different individual subjects.
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
14.
ELECTRO-CATHETER WITH INNER LUMEN FOR DRUG DELIVERY
An electro-catheter for delivering electrical stimulation to an anatomical target (e.g., a dorsal root ganglion) includes an inner lumen for delivering a pharmacological agent to the anatomical target. The catheter includes a catheter body extending along a length from a first end to a second end about a central axis. An electrode assembly is arranged at the second end of the catheter body to deliver electrical stimulation to the anatomical target. The inner lumen extends through the catheter body to deliver the pharmacological agent to the anatomical target. A port is formed in the catheter body such that the port is in fluid communication with the inner lumen.
Disclosed herein are Clostridium neurotoxin (BoNT) or SNARE cleaving homologue variants, constructs, and methods of use. The BoNT or SNARE cleaving homologue variants can include one or more amino acid or domain substitutions, deletions, or insertions in the light chain.
Synthetic vascular conduits are constructed to have patterned microchannels on the blood-contacting surface of the vascular conduits. Endothelial cells are seeded in the microchannels. The patterned microchannels protect the seeded endothelial cells from wall shear stress, increasing the retention of endothelial cells in the vascular conduits under physiological conditions. The microchannels are patterned to optimize total surface area protected from wall shear stress and/or endothelial cell migration distance between microchannels.
Provided herein are therapeutic agents having specificity for human CLPTM1L/CRR9 polypeptide, including therapeutic agents comprising one or more CLPTM1L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function). In particular, provided herein are fully human monoclonal antibodies against human CLPTM1L/CRR9 protein and methods of using such antibodies for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1L/CRR9 protein dysfunction (e.g., pathogenic production, modification, or function).
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
18.
DETECTING INFLUENZA AND OTHER RESPIRATORY INFECTIONS FROM ELECTROCARDIOGRAPHY DATA USING MACHINE LEARNING
Electrocardiography (ECG) data acquired from a subject and processed with a machine learning model to determine whether the subject has, or is developing, an influenza infection. The machine learning model generates classified feature data that are indicative of the presence and/or likelihood of an influenza infection. Scalogram and/or spectrogram data may be generated from the ECG data and processed with a machine learning model to determine whether the subject has, or is developing, a respiratory infection, such as an influenza or COVID-19 infection. The machine learning model generates classified feature data that are indicative of the presence and/or likelihood of a respiratory infection.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
A61B 5/308 - Input circuits therefor specially adapted for particular uses for electrocardiography [ECG]
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Disclosed are RNAs comprising a fragment of a Y-RNA, e.g., Y5-RNA or Y1-RNA, expression vectors encoding the same, cells and extracellular vesicles comprising the RNAs, pharmaceutical compositions, and methods of using the preceding for the treatment of disease and disorders, e.g., diseases and disorders associated with endothelial senescence.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 9/00 - Drugs for disorders of the cardiovascular system
20.
HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF
This disclosure relates to heterocyclic compounds of Formula (I), Formula (II), and Formula (III) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I), Formula (II), and Formula (III) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy. Formula (I), Formula (II), Formula (III).
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
An aortic cannula includes a tubular body extending along a central axis from a first end to a second end, and having three separate lumens. A side port is formed in an outer surface of the tubular body at the second end of the tubular body. The first lumen is formed within the tubular body to supply blood flow to an aorta of a subject. The second lumen delivers an embolic protection device to the aorta of the subject, where the second lumen is contained within the first lumen and is coaxial with the central axis of the tubular body. The third lumen is fluidically coupled to the side port to provide delivery of a cardioplegia solution and/or aortic root vent suction.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61M 29/00 - Dilators with or without means for introducing media, e.g. remedies
A61M 60/139 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting inside the aorta, e.g. intra-aortic balloon pumps
22.
Improved Compositions and Methods for Targeting Mitochondria in Cancer Cells
The present disclosure provides compounds of formula (I′) and uses thereof for the treatment of cancer. Also provided are pharmaceutical compositions and kits comprising the same compounds. The present compounds may have improved anti-tumor effect and reduced toxicity and may be useful for targeting mitochondria in cancer cells.
Ferrous and non-ferrous materials are identified and classified in a subject using a machine learning model that receives single-energy CT image data as an input. The machine learning model may be trained on single-energy CT image data. Additionally or alternatively, the machine learning model may be trained on dual-energy CT image data, geometrical data about metal objects, CT number data derived from the single-energy and/or dual-energy CT image data, and/or acquisition parameter data pertaining to acquisition parameters used when acquiring the single-energy and/or dual-energy CT image data. Single-energy CT image data acquired from a subject is input to the machine learning model, generating classified feature data as an output. The classified feature data indicate the presence of ferrous metal in the subject.
This invention relates to methods and compositions for assessing risk by measuring total and specific cell-free nucleic acids (such as DNA) in a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant rejection.
Disclosed herein are methods for weight loss and/or for reducing weight gain. The methods can include administering to a subject reutericyclin and a GLP-1 receptor agonist. Additional methods for weight loss and/or reducing weight gain include administering to a subject reutericyclin and a SGLT-2 inhibitor.
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
26.
RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (TPA) FRAGMENTS AND USES THEREOF
VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC. (USA)
THE MEDICAL COLLEGE OF WISCONSIN, INC. (USA)
Inventor
Zheng, Ze
Dai, Wen
Lund, Hayley
Kastrup, Christian
Abstract
The present technology relates to recombinant polypeptides, or nucleotides encoding the same, comprising tissue plasminogen activator (tPA) fragments and uses thereof for treating cardiovascular diseases. In some embodiments, the tPA fragments comprise the kringle 2 domain of tPA.
An end-capped (N-acetylated, C-amidated) dual-domain peptide called hE-HMGBl-BP was designed to bind and deplete HMGB1 from circulation via uptake by the liver's heparin sulfate proteoglycan (HSPG) system.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
vv1.7 voltage gated sodium channels, polynucleotides encoding the polypeptide aptamers, and infectious particles as well as methods of using the same in the treatment of diseases and disorders, for example, neuropathic pain.
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.
Disclosed herein are compositions and methods for treating, and for the preventative treatment of, a subject diagnosed with or at risk of breast cancer, including triple negative breast cancer, and/or a subject diagnosed with or at risk of lung cancer.
Disclosed are methods of treating graft versus host disease (GVHD) or treating ocular graft versus host disease (oGVHD). The methods may comprise administering a therapeutically effective amount of a composition comprising CCL20 locked dimer to a subject, e.g., a subject suffering from GVHD. Also disclosed are modified CCL20LD compositions comprising an unstructured polypeptide.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Systems and methods for accelerated online adaptive radiation therapy (“ART”) are described. The improvements to online ART are generally provided based on the use of textural analysis and machine learning algorithms implemented with a hardware processor and a memory. The described systems and methods enable more efficient and accurate online adaptive replanning (“OLAR”), which can also be implemented in clinically acceptable timeframes. For example, OLAR can be reduced from taking 10-30 minutes down to 5-10 minutes.
G06T 7/149 - SegmentationEdge detection involving deformable models, e.g. active contour models
G06T 7/174 - SegmentationEdge detection involving the use of two or more images
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
33.
Augmented Reality-Driven Guidance for Interventional Procedures
Described here are systems and methods for guiding interventional procedures, in which the guidance is driven by a virtual reality, augmented reality, augmented virtuality, and/or other mixed reality systems. The virtual/mixed reality guidance can be based on magnetic resonance images that are acquired in real-time and presented to a user in a virtual/mixed reality environment.
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
34.
Far red and near infrared light-mediated conditioning of tissues and/or blood to prevent reperfusion injury in endovascular therapies
Reperfusion injury is limited during endovascular therapies (e.g., revascularization and/or reperfusion of end organ tissues) by conditioning the tissues against reperfusion injury using an optical fiber catheter to deliver far red and near infrared (R/NIR) light to the tissues. The light may be multiple wavelength or single wavelength light, and may have one or more wavelengths selected from the range of 510 to 830 nm. The R/NIR light may be delivered concurrently with the endovascular therapy, or in other instances may be delivered before or after a particular therapy.
A61B 18/24 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor with a catheter
A61B 17/00 - Surgical instruments, devices or methods
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
35.
Method and Apparatus for Limiting Growth of Eye Length
Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
Laser-Speckle Contrast imaging apparatus configured to assess and quantify motion associated with an object and, in a specific case of an eye-retinal vascular anatomy and hemodynamics and generate substantially contrast-free maps of retinal blood flow over a wide field-of-view at up to 590 fps and under short exposure durations (>50 μs), is applicable for diagnosis, study, and management of neurodegenerative conditions (i.e. mild cognitive impairment and Alzheimer's disease) and systemic cardiovascular diseases (i.e. athero- and arteriosclerosis, coronary artery occlusion, and hypertension). The apparatus employs a) a set of apertures substantially blocking light, delivered from a source of light to an illumination arm of the apparatus, from impinging onto an axial point of the front surface of the lens of the illumination arm, and b) polarization gating between the illumination and light-collecting arms of the apparatus. In one implementation, the apparatus is configured to allow for irradiation of the object with an optical field a degree of coherence and/or spectral content of which are varied delivered through the same optical train including the set of apertures.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
37.
MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND
The morphology of an anatomical target is monitored using ultrasound to confirm when the anatomical target's morphology is substantially aligned, or otherwise in agreement, with a reference morphology indicated by a radiation treatment plan and determined from pre-treatment ultrasound data. Ultrasound data are acquired to measure and monitor the morphology of an anatomical target, such as the bladder, rectum, stomach, or the like. The ultrasound data are compared to reference data. When the morphology of the anatomical target is substantially aligned, or otherwise in agreement, with the anatomical morphology indicated by the reference data and the radiation treatment plan, then the patient can be provided with the planned radiation treatment for that day.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
38.
CORONARY PLAQUE SAMPLING METHOD FOR ASSESSING CORONARY ATHEROSCLEROSIS AND IDENTIFYING RELATED BIOMARKERS
Atherosclerosis is a leading cause of morbidity and mortality. The current knowledge of atherosclerotic plaques is primarily based on studies of animal models, expired patients, or peripheral arterial plaques. A coronary plaque biopsy method that combines RNA retrieval from balloons used in percutaneous coronary interventions (PCI) and inexpensive, low-input transcriptome profiling using SMART-seq is presented. Leveraging prior single cell RNA-Seq data from coronary plaques in explanted hearts, biomarkers indicative of cell types differentially expressed in coronary plaque biopsy specimens from acute coronary syndrome (ACS) patients and stable coronary artery disease (sCAD) patients. In addition, the method can identify significant differential expression of over 150 genes in coronary plaque biopsy specimens between patients with sCAD and ACS.
Disclosed herein are novel serotonin 5-HT2A receptor agonists with selectivity for the 5-HT2A receptor subtype over other serotonin receptors. Some of these 5-HT2A agonists exhibit functional selectivity and preferentially activate arrestin signaling over G protein-mediated signaling. Also disclosed are pharmaceutical compositions of the compounds and methods of treating certain diseases or conditions.
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
C07D 217/04 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
The present invention provides methods and kits for detecting cilium markers in samples and uses thereof for detecting and treating endothelial damage or dysfunction or vascular injury in the subject. In one aspect, the disclosure provides a method of detecting endothelial damage or dysfunction or vascular injury in a subject in need thereof, the method comprising: detecting one or more markers of cilium in a biological sample from the subject, wherein a higher level of cilium detected in the biological sample compared to control indicates endothelial damage or dysfunction or vascular injury.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
41.
Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition
The disclosure relates to quinazoline derivatives, pharmaceutical compositions, and therapeutic methods related thereto. In certain embodiments, this disclosure relates to compounds and methods of treating or preventing a Nox-related disease comprising administering to a subject a pharmaceutical composition comprising a Nox inhibitor or derivative reported herein.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present disclosure provides polyphenolic boronates and mitochondria-targeted polyphenolic boronates and pharmaceutical compositions thereof. The present compounds may be useful for treating cancer and reducing or inhibiting cancer cell growth. The present compounds may be useful for reducing or analyzing reactive oxygen and nitrogen species in tumor microenvironment of a cancer. The present compounds may target mitochondria in carcer cells and have improved anti-tumor effect and reduced toxicity.
Disclosed are bispecific single-chain constructs, pharmaceutical compositions comprising the constructs, methods of treatment using the pharmaceutical compositions, polynucleotides encoding the constructs, and methods of making the constructs.
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
44.
INTERFEROMETRIC LASER SPECKLE CONTRAST IMAGING SYSTEM AND METHOD
An interferometric laser speckle contrast optical system configured to limit depth of field in order to image only a thin curved object layer of a chosen object while distinguishing such layer from the surrounding curved layers that substantially are not being imaged. The system utilizes a novel 5F-optical arrangement in a sample arm of the constituent interferometer to substantially match the curvature of the surface of illumination with that of the targeted object layer, thereby increasing the spatial resolution and reducing the signal-to-noise ratio of the imaging process. When used as part of an ophthalmoscope, the system for hemodynamic alterations to be measured with substantially capillary level resolution and to establish normative baseline values for retinal neurovascular function.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
The present disclosure provides novel inhibitors of PBRM1, specifically the 2nd bromodomain of PBRM1 (PBRM1-BD2), pharmaceutical compositions and methods of use thereof.
C07C 229/58 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho- position having the nitrogen atom of at least one of the amino groups further bound to a carbon atom of a six-membered aromatic ring, e.g. N-phenyl-anthranilic acids
C07C 251/24 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
This invention relates to methods and compositions for assessing or monitoring an amount of mitochondrial cell-free DNA and/or nuclear cell-free DNA from a subject to assess cellular or tissue injury and/or risk in the subject. The amount(s) can be compared to specific threshold values, in some embodiments, to assess the subject and/or guide treatment of the subject.
The present invention provides constructs comprising modified riboswitches to regulate expression of a transgene within a subject. Methods of treating a disease, specifically an eye disease, are also contemplated.
A compression device is used to increase intra-luminal pressure within the upper esophageal sphincter of a patient in order relieve an impact of an abnormal or defective upper esophageal sphincter anatomy, physiology, or functionality. In one implementation, the compression device is used in conjunction with an external pressure sensing device to determine the external pressure that is to be applied to the cricoid for a specific patient. The compression device can be a means for the management and/or treatment of abnormal upper esophageal sphincter functionality, or a means for strengthening an esophageal sphincter of a subject, or a means for curing esophageal reflux disease of a subject, or a means for improving vocal function in a subject, or a means for managing lung aspiration, or a means for applying cricoid pressure during anesthesia intubation, or a means for stabilizing body structures such as during medical imaging or radiation treatment.
A colpotomy system includes a colpotomy cup, an electromagnet that is coupled to the colpotomy cup (thereby forming an electromagnetic colpotomy cup), and a bipolar electrocautery wand configured for use with the colpotomy cup and electromagnet. The electromagnet is used to generate an inwardly directed force, known as the Lorentz force, to direct the electrocautery wand towards the center of the colpotomy cup. This allows the physician to direct the wand towards the center of the uterine axis and away from the bladder as well as other surrounding structures in the pelvic cavity.
The present invention provides methods of reducing, inhibiting, preventing and treating vascular diseases. More specifically, the present disclosure provides methods of treating vascular diseases with the modulator of p66Shc signaling SHetA2.
Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
52.
MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS
The present disclosure provides mitochondria-targeted N-acetylcysteine compounds and pharmaceutical compositions thereof. The present compounds may be useful for treating cancer and enhancing CAR-T cell therapy. The present compounds may be isotopically labeled, which may be useful for labeling and analyzing a sample. The present compounds may target mitochondria in carcer cells and have improved anti-tumor effect and reduced toxicity.
In the present invention, the inventors provide substituted the hydroxyl group in hydroxyurea (HU) with a triphenylphosphonium (TPP) cation attached to an alkyl group with different chain lengths, generating a new class of mitochondria-targeted hydroxyurea compounds (Mito-HUs). Elongating the alkyl side chain length increased the hydrophobicity of Mito-HUs, and correlated with increased inhibition of oxidative phosphorylation, and antiproliferative effects in tumor cells.
Electronic tumor marker values are generated from patient health data using a suitably trained machine learning model. In general, the electronic tumor marker data include estimated values of an electronic tumor marker that is analogous or otherwise complementary to carbohydrate antigen 19-9 ("CA19-9") biomarkers measured from a patient or biological specimen.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
56.
USE OF IMMUNOGENIC T CELL EPITOPES FOR LYME DISEASE VACCINATION AND DIAGNOSIS
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
57.
Medical Image Segmentation Using Deep Learning Models Trained with Random Dropout and/or Standardized Inputs
Systems and methods are described for segmenting medical images, such as magnetic resonance images, using a deep learning model that has been trained using random dropped inputs, standardized inputs, or both. Medical images can be segmented based on anatomy, physiology, pathology, other properties or characteristics represented in the medical images, or combinations thereof. As one example, multi-contrast magnetic resonance images are input to the trained deep learning model in order to generate multiple segmented medical images, each representing a different segmentation class.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06T 7/143 - SegmentationEdge detection involving probabilistic approaches, e.g. Markov random field [MRF] modelling
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
The present invention provides methods of treating airway reflux using an HIV protease inhibitor that is capable of binding to and inhibiting the enzymatic activity of pepsin. Compositions comprising sustained release formulations of HIV protease inhibitors are also provided for oral administration.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/665 - Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Laser-Speckle Contrast imaging apparatus configured to assess and quantify motion associated with an object and, in a specific case of an eye—retinal vascular anatomy and hemodynamics and generate substantially contrast-free maps of retinal blood flow over a wide field-of-view at up to 590 fps and under short exposure durations (>50 μs), is applicable for diagnosis, study, and management of neurodegenerative conditions (i.e. mild cognitive impairment and Alzheimer's disease) and systemic cardiovascular diseases (i.e. athero- and arteriosclerosis, coronary artery occlusion, and hypertension). The apparatus employs a) a set of apertures substantially blocking light, delivered from a source of light to an illumination arm of the apparatus, from impinging onto an axial point of the front surface of the lens of the illumination arm, and b) polarization gating between the illumination and light-collecting arms of the apparatus. In one implementation, the apparatus is configured to allow for irradiation of the object with an optical field a degree of coherence and/or spectral content of which are varied delivered through the same optical train including the set of apertures.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
61.
SUSTAINED-RELEASE ORAL FOSAMPRENAVIR FORMULATION FOR TREATMENT OF REFLUX
The present invention provides methods of treating airway reflux using an HIV protease inhibitor that is capable of binding to and inhibiting the enzymatic activity of pepsin. Compositions comprising sustained release formulations of HIV protease inhibitors are also provided for oral administration.
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
62.
SUSTAINED-RELEASE ORAL FOSAMPRENAVIR FORMULATION FOR TREATMENT OF REFLUX
C07F 9/655 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
A prosthetic heart valve is constructed from a flexible substrate that can be folded from an unfolded configuration to a folded configuration, in which the prosthesis is operable as a prosthetic heart valve. The prosthetic heart valves can be designed as atrioventricular valves (e.g., tricuspid valve, mitral valve) or as semilunar valves (e.g., aortic valve, pulmonary valve).
This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (USA)
Inventor
Marchant, Jonathan S.
Sprague, Daniel J.
Spicer, Timothy Patrick
Scampavia, Louis
Abstract
The present disclosure provides novel chemotypes, pharmaceutical compositions thereof, and method of use thereof for treating parasitic infection, including infection caused by parasitic flatworms. The present compounds may be useful as alternatives to praziquantel and may have improved activities against parasitic infections, particularly parasitic flatworm infections.
The present disclosure provides inhibitory peptides of mitochondrial fission protein 1 (Fis1), polynucleotides and vectors encoding the peptides, and methods of using the peptides to treat diseases, including arterial diseases and vascular dysfunction associated with type 2 diabetes.
36 - Financial, insurance and real estate services
Goods & Services
Promoting public interest and awareness of cancer, cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events Charitable fundraising services for promoting cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events
36 - Financial, insurance and real estate services
Goods & Services
Promoting public interest and awareness of cancer, cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events Charitable fundraising services for promoting cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events
36 - Financial, insurance and real estate services
Goods & Services
Promoting public interest and awareness of cancer, cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events Charitable fundraising services for promoting cancer education, research and trials, and cancer diagnosis, prevention, and treatment by means of bike riding events
70.
ASSESSING RISK WITH PRE-OPERATIVE TOTAL CELL-FREE DNA
This invention relates to methods and compositions for assessing risk based on amount(s) of total cell-free DNA in a subject, such as including at least one pre-operative sample from the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
71.
IMMUNE TOLERANCE INDUCTION FOR AUTO-IMMUNE DISEASES THROUGH PLATELET TARGETED GENE THERAPY INVOLVING MYELIN OLIGODENDROCYTE GLYCOPROTEIN (MOG) POLYPEPTIDE.
Disclosed herein are methods and compositions for inducing immune tolerance in a subject. The methods comprise expressing the truncated MOG polypeptide described herein in HSC and transplanting HSC in a subject in need to induce immune tolerance.
Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
Multispectral magnetic resonance image data having multiple different contrast weightings (e.g., T1 weighting, T2 weighting, proton density weighting, inversion recovery weighting) are acquired in a single data acquisition. Different sets of multispectral data are acquired using an interleaved acquisition, in which data with different contrast weightings are acquired at different interleaved sets of spectral bins. Additionally or alternatively, frequency-encoding gradient polarity can be reversed for different interleaves in order to perform residual artifact compensation.
Enhanced multispectral data, spectral bin images reconstructed therefrom, and/or composite images generated from spectral bin images are generated using deep learning-based techniques. As one example, a bin combination approach can be used to improve spatial resolution. As another example, a super-resolution technique can be used to improve spatial resolution. As yet another example, a contrast transformation technique can be used to generate images with a different contrast weighting from multispectral data acquired from a metal-containing region.
Multiomics integration analysis is provided using machine learning and model interpretation. Feature data that indicate connections between different layers of a multiomics dataset are generated. Based on these feature data, connections between a first type of omics data (e.g., proteomics data) and a second type of omics data can be determined. One or more machine learning algorithms or models are used to generate output data, from which model interpretation data are generated, and based on which feature data that indicate interactions between biomolecules across layers of omics data are generated.
Quantitative parameter maps are generated from multispectral data acquired using a multispectral imaging ("MSI") technique. In general, the quantitative parameter maps—which may include T1 maps, T2 maps, and within-bin off-resonance frequency maps—are generated using a magnetic resonance fingerprinting ("MRF") framework.
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
G01R 33/44 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
G01R 33/50 - NMR imaging systems based on the determination of relaxation times
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
Promoting public awareness of environmental and sustainability issues and initiatives; promoting public awareness of environmental matters; providing information in the area of sustainable business solutions
78.
Systems and methods for estimating histological features from medical images using a trained model
Systems and methods for estimating quantitative histological features of a subject's tissue based on medical images of the subject are provided. For instance, quantitative histological features of a tissue are estimated by comparing medical images of the subject to a trained model that relates histological features to multiple different medical image contrast types, whether from one medical imaging modality or multiple different medical imaging modalities. In general, the trained model is generated based on medical images of ex vivo samples, in vitro samples, in vivo samples or combinations thereof, and is based on histological features extracted from those samples. A machine learning algorithm, or other suitable learning algorithm, is used to generate the trained model. The trained model is not patient-specific and thus, once generated, can be applied to any number of different individual subjects.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
79.
MULTI-SPECTRAL SUSCEPTIBILITY-WEIGHTED MAGNETIC RESONANCE IMAGING
The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
82.
COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA
This invention relates to compositions and methods for treating subjects in need of mechanical support, such as those who have had surgery and/or are in need of pro-inflammatory reduction. The mechanical support can comprise a filter that reduces the amount of cell-free DNA in the subject, in some embodiments. The subject may be treated with cf-DNA inhibitors in other embodiments.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
THE MEDICAL COLLEGE OF WISCONSIN, INC. (USA)
Inventor
Jacobson, Kenneth A.
Fallot, Lucas B.
Ravi, Rama S.
Fisher, Courtney L.
Auchampach, John A.
Salmaso, Veronica
Pradhan, Balaram
Keyes, Robert F.
Smith, Brian C.
Abstract
Disclosed are compounds of the formula (I): wherein R1-R5122 are as defined in the specification, pharmaceutical salts thereof and stereoisomers thereof, and pharmaceutical compositions containing one or more of these compounds, salts, or stereoisomers thereof. Also disclosed is a method of treating a having a condition selected from the group consisting of chronic neuropathic pain, heart disease, suppressed immunity, and a disease of the liver, psoriasis, and cancer by administering to the subject having such a condition an effective amount of the compound or pharmaceutical composition.
A61P 37/00 - Drugs for immunological or allergic disorders
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
84.
Gene Expression Signature for Predicting Immunotherapy Response and Methods of Use
The present invention provides novel gene signature associated with immune checkpoint inhibitor (ICT) named ImmuneCells.Sig which is predicative of ICT outcomes of melanoma patients which is significantly more accurate than all previously reported ICT response signatures. The ImmuneCells.Sig can be used as an accurate predictor of ICT response and may be used to determine if a patient will be susceptible and respond to ICT treatment.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
An embolic protection device includes an expandable mesh net coupled to a catheter assembly used in an interventional procedure. The catheter assembly includes an outer catheter, an inner catheter, a compliant balloon, and the mesh net. The catheter assembly can be deployed in a lumen, such as an outflow graft of a left ventricular assist device, a blood vessel, or other bodily lumen. The mesh net is coupled to the inner catheter and is expanded by retracting the outer catheter when positioned in the lumen. The mesh net captures embolic debris before it is able to enter into the patient's blood stream.
A61F 2/01 - Filters implantable into blood vessels
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
The present invention provides methods and kits for detecting and treating multiple myeloma. The methods involve detecting proteins that the inventors have identified as biomarkers of multiple melanoma.
This invention relates to methods and compositions for assessing or monitoring an amount of donor-specific fraction cell-free DNA from a transplant subject and comparing to specific threshold values for making treatment management decisions.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention provides methods and immunoassays kits for the improved detection of cytomegalovirus (CMV) in a subject. In some embodiments, the methods and immunoassays kits differentiate between subjects who have developed a serological response to vaccination against CMV and subjects who have had a natural infection. In some embodiments, the methods and immunoassays kits differentiate between serological responses to different CMV serotypes.
The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A computer-based system that includes one or more computing devices configured to receive user input comprising a plurality of parameters indicating a condition of a trauma patient, the plurality of parameters comprising at least one patient reported outcome; apply the plurality of parameters to a predictive model trained to determine, based on the plurality of parameters, a quality of life designation for the patient; and transmit the quality of life designation to a user computing device for display on the user computing device.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Disclosed is an endoscope for measuring intra-organ pressure (e.g., intragastric pressure), and more particularly an endoscope for measuring intra-organ pressure (e.g., intragastric pressure) and visualizing the response of an adjacent sphincter (e.g., lower esophageal sphincter) to changes in the intra-organ pressure.
A61B 5/03 - Measuring fluid pressure within the body other than blood pressure, e.g. cerebral pressure
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
A61B 1/273 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the upper alimentary canal, e.g. oesophagoscopes, gastroscopes
93.
INDICATOR CLEARANCE MONITORING IN MACHINE PERFUSION OF AN ORGAN
A system for monitoring an organ in vitro, comprising: a machine perfusion apparatus for perfusing the organ with a perfusate comprising an indicator; a spectrometer coupled to an input flow cell and an output flow cell, the input flow cell fluidically coupled to a perfusate recirculation input to the machine perfusion apparatus, and the output flow cell fluidically coupled to a physiological fluid output from the organ; and a controller comprising a processor coupled to the input flow cell, the output flow cell, and the spectrometer.
A system for monitoring an organ in vitro, comprising: a machine perfusion apparatus for perfusing the organ with a perfusate comprising an indicator; a spectrometer coupled to an input flow cell and an output flow cell, the input flow cell fluidically coupled to a perfusate recirculation input to the machine perfusion apparatus, and the output flow cell fluidically coupled to a physiological fluid output from the organ; and a controller comprising a processor coupled to the input flow cell, the output flow cell, and the spectrometer.
The present disclosure provides compounds of formula (I') and uses thereof for the treatment of cancer. Also provided are pharmaceutical compositions and kits comprising the same compounds. The present compounds may have improved anti-tumor effect and reduced toxicity and may be useful for targeting mitochondria in carcer cells.
This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Described herein are methods for treating COVID-19 or preventing COVID-19 in a subject exposed to SARS-CoV-2 by administering to the subject a therapeutically effective amount of salmeterol or the pharmaceutically acceptable salt thereof.
A compound of Formula I, which possesses 5-HT2A and/or 5-HT2C selective receptor activity, but lacks at lease some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
A compound of Formula I, which possesses 5-HT2A and/or 5-HT2C selective receptor activity, but lacks at lease some of the undesirable characteristics of 5-HT2B-agonist related activities, is disclosed. Methods of preparing said compounds are also described. The compound of Formula I may be useful in the treatment of depression, alcoholism, tobacco and cocaine addiction, inflammation, cluster headache, PTSD, seizure disorders and other CNS disorders.
This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a subject having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. This invention also relates to compositions and methods for treating subjects having or suspected of having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. In embodiments, there is a risk of an inappropriate or detrimental pro-inflammatory response, such as in a subject with a COVID-19 infection. The methods and composition provided herein can be used to determine severity and risk of complications in a subject. The methods and composition provided herein can also be used to assess the effectiveness of a therapy in a subject, such as a COVID-19 subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
100.
Method and apparatus for limiting growth of eye length
Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
